Antares Pharma, Inc. – NASDAQ:ATRS
Antares Pharma stock price today
$5.59
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 1 hour
Antares Pharma stock price monthly change
+0.36%
month
Antares Pharma stock price quarterly change
+65.88%
quarter
Antares Pharma stock price yearly change
+37.01%
year
Antares Pharma key metrics
Market Cap | N/A |
Enterprise value | 914.65M |
P/E | 14.94 |
EV/Sales | 4.98 |
EV/EBITDA | 15.05 |
Price/Sales | 5.18 |
Price/Book | 5.40 |
PEG ratio | -0.84 |
EPS | 0.24 |
Revenue | 183.45M |
EBITDA | 60.74M |
Income | 42.46M |
Revenue Q/Q | -1.24% |
Revenue Y/Y | 15.66% |
Profit margin | 23.15% |
Oper. margin | 31.46% |
Gross margin | 61.52% |
EBIT margin | 31.46% |
EBITDA margin | 33.11% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAntares Pharma stock price history
Antares Pharma stock forecast
Antares Pharma financial statements
| Jun 2021 | 44.97M | 6.70M | 14.91% |
|---|---|---|---|
| Sep 2021 | 48.19M | 5.39M | 11.19% |
| Dec 2021 | 48.73M | 32.68M | 67.07% |
| Mar 2022 | 41.55M | -2.32M | -5.59% |
| 2021-08-05 | 0.02 | 0.03 |
|---|---|---|
| 2021-11-04 | 0.03 | 0.03 |
| 2022-03-03 | 0.01 | 0.19 |
| Jun 2021 | 212619000 | 80.59M | 37.9% |
|---|---|---|---|
| Sep 2021 | 216739000 | 75.91M | 35.02% |
| Dec 2021 | 257505000 | 81.74M | 31.75% |
| Mar 2022 | 255658000 | 79.89M | 31.25% |
| Jun 2021 | 6.43M | -1.27M | -15.68M |
|---|---|---|---|
| Sep 2021 | 18.71M | -2.50M | -3.97M |
| Dec 2021 | 9.49M | 1.10M | -2.05M |
| Mar 2022 | -4.88M | 666K | 17K |
Antares Pharma alternative data
| Aug 2023 | 201 |
|---|---|
| Sep 2023 | 201 |
| Oct 2023 | 201 |
| Nov 2023 | 201 |
| Dec 2023 | 201 |
| Jan 2024 | 201 |
| Feb 2024 | 201 |
| Mar 2024 | 201 |
| Apr 2024 | 201 |
| May 2024 | 201 |
| Jun 2024 | 201 |
| Jul 2024 | 201 |
Antares Pharma other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2020 | 16400 | 0 |
| Jan 2021 | 0 | 20000 |
| Feb 2021 | 0 | 1234741 |
| Mar 2021 | 0 | 50000 |
| Jul 2021 | 0 | 100000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | JACOB LEONARD S director | Stock Option (right to buy) | 24,679 | $2.24 | $55,281 | ||
Sale | GUETH ANTON director | Common Stock | 100,000 | N/A | N/A | ||
Option | GUETH ANTON director | Common Stock | 40,000 | N/A | N/A | ||
Option | GUETH ANTON director | Stock Option (right to buy) | 40,000 | N/A | N/A | ||
Option | GUETH ANTON director | Common Stock | 72,669 | $1.66 | $120,631 | ||
Option | GUETH ANTON director | Stock Option (right to buy) | 72,669 | $1.66 | $120,631 | ||
Option | GARRITY THOMAS J director | Common Stock | 50,000 | $1.12 | $56,000 | ||
Sale | GARRITY THOMAS J director | Common Stock | 50,000 | $1.12 | $56,000 | ||
Option | GARRITY THOMAS J director | Stock Option (right to buy) | 50,000 | $1.12 | $56,000 | ||
Sale | GRAHAM PETER J officer: EVP Gene.. | Common Stock | 45,000 | N/A | N/A |
| Patent |
|---|
Grant Utility: Prefilled syringe injector Filling date: 11 Oct 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 10 Jun 2019 Issue date: 20 Sep 2022 |
Application Filling date: 10 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 1 Nov 2021 Issue date: 28 Apr 2022 |
Grant Filling date: 19 Apr 2019 Issue date: 5 Apr 2022 |
Application Filling date: 5 Oct 2021 Issue date: 31 Mar 2022 |
Application Filling date: 29 Nov 2021 Issue date: 17 Mar 2022 |
Application Filling date: 18 Aug 2021 Issue date: 17 Mar 2022 |
Application Filling date: 27 Oct 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 7 Aug 2015 Issue date: 7 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2021 3 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 4 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 5 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 6 May 2021 | Q1 2021 Earnings Call Transcript |
-
What's the price of Antares Pharma stock today?
One share of Antares Pharma stock can currently be purchased for approximately $5.59.
-
When is Antares Pharma's next earnings date?
Unfortunately, Antares Pharma's (ATRS) next earnings date is currently unknown.
-
Does Antares Pharma pay dividends?
No, Antares Pharma does not pay dividends.
-
What is Antares Pharma's stock symbol?
Antares Pharma, Inc. is traded on the NASDAQ under the ticker symbol "ATRS".
-
What is Antares Pharma's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Antares Pharma?
Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Antares Pharma's key executives?
Antares Pharma's management team includes the following people:
- Mr. Robert F. Apple Chief Executive Officer, Pres & Director(age: 59, pay: $1,000,000)
- Mr. Fred M. Powell Executive Vice President & Chief Financial Officer(age: 64, pay: $636,390)
- Mr. Peter J. Graham Executive Vice President of HR, Gen. Counsel, Chief Compliance Officer & Corporation Sec.(age: 58, pay: $634,480)
-
How many employees does Antares Pharma have?
As Jul 2024, Antares Pharma employs 201 workers.
-
When Antares Pharma went public?
Antares Pharma, Inc. is publicly traded company for more then 28 years since IPO on 3 Oct 1996.
-
What is Antares Pharma's official website?
The official website for Antares Pharma is antarespharma.com.
-
Where are Antares Pharma's headquarters?
Antares Pharma is headquartered at SUITE 300, 100 PRINCETON SOUTH, Ewing, NEW JERSEY.
-
How can i contact Antares Pharma?
Antares Pharma's mailing address is SUITE 300, 100 PRINCETON SOUTH, Ewing, NEW JERSEY and company can be reached via phone at +1 609 359 3020.
Antares Pharma company profile:
Antares Pharma, Inc.
antarespharma.comExchange:
NASDAQ
Full time employees:
201
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
SUITE 300, 100 PRINCETON SOUTH
Ewing, NEW JERSEY 08628
Ewing, NEW JERSEY 08628
CIK: 0001016169
ISIN: US0366421065
CUSIP: 036642106
